UBS Group
ZJYL

UBS Group’s Jin Medical International ZJYL Stock Holding History

UBS Group’s Portfolio ZJYL Stock Details ZJYL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.47K Buy
1,223
+999
+446% +$2.96K ﹤0.01% 9267
2025
Q4 		$987 Sell
224
-1,860
-89% -$11K ﹤0.01% 9740
2025
Q3 		$23.6K Sell
2,084
-2,608
-56% -$33.3K ﹤0.01% 8047
2025
Q2 		$61K Sell
4,692
-3,835
-45% -$58.4K ﹤0.01% 7610
2025
Q1 		$127K Sell
8,527
-1,024
-11% -$17K ﹤0.01% 6862
2024
Q4 		$149K Buy
9,551
+9,446
+8,996% +$296K ﹤0.01% 6632
2024
Q3 		$5.64K Sell
105
-3,551
-97% -$214K ﹤0.01% 8039
2024
Q2 		$190K Buy
3,656
+3,644
+30,367% +$230K ﹤0.01% 5689
2024
Q1 		$945 Sell
12
-536
-98% -$78.4K ﹤0.01% 8297
2023
Q4 		$136K Buy
+548
New +$18.6K ﹤0.01% 6010
2023
Q3 		– Sell
-746
Closed -$8.51K – 10046
2023
Q2 		$8.51K Buy
+746
New +$5.67K ﹤0.01% 7234

Other funds holding ZJYL

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's ZJYL Position: Q1 2026 in Review

UBS Group increased its Jin Medical International (ZJYL) stake by 446% in Q1 2026, buying an estimated $2.96K and bringing the position to 1,223 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #9267.

UBS Group first reported a position in ZJYL in Q2 2023 and has held it in 11 quarters since. The position peaked at $190K in Q2 2024. 2 funds tracked by Wall St. Rank hold ZJYL as of Q1 2026.

  • UBS Group held 1,223 shares of Jin Medical International worth $2.47K as of Q1 2026.
  • UBS Group bought 999 Jin Medical International shares in Q1 2026, an estimated $2.96K.
  • Jin Medical International made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9267 holding.
  • UBS Group first reported a position in Jin Medical International in Q2 2023 and has held it in 11 quarters since.
  • UBS Group's Jin Medical International position peaked at $190K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Jin Medical International as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.